We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

subscriber-only content

LOG-IN

SUBSCRIBE NOW

for more website access

The content of this section is only available to Investors Chronicle online subscribers.

Shire hits new heights

A particularly strong fourth quarter, aided by a healthy contribution from newly-acquired Advanced BioHealing (ABH), helped Shire Pharmaceuticals break the $4bn (£2.5bn) sales barrier for the first time and cement its place as the fastest growing of the UK's big pharmaceutical companies.

subscriber-only content

LOG-IN

SUBSCRIBE NOW

visible-status-Subscription-Only story-url-Shire prelims 2011 09 feb 12.xml

By Julian Hofmann,
09 February 2012

Print this article Share this article